This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Shire To Present Scientific Data Across A Range Of Psychiatric Disorders At American Psychiatric Association Annual Meeting

PHILADELPHIA, May 17, 2013 /PRNewswire/ --

Research explores data on treatments for psychiatric disorders; health economics and outcomes research also  to  be presented

Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announces that it will present scientific data in 7 poster presentations at the American Psychiatric Association (APA) 166th Annual Meeting in San Francisco, May 18-22. The data being presented represent Shire's ongoing commitment to the clinical research of Vyvanse ® (lisdexamfetamine dimesylate) Capsules, (CII) and INTUNIV® (guanfacine) Extended-Release Tablets, its approved prescription medicines for Attention-Deficit/Hy​​peractivity Disorder (ADHD). Data being presented include post-hoc analyses from several of its phase 2 clinical studies investigating potential new psychiatric uses of Vyvanse for the adjunctive treatment for Major Depressive Disorder (MDD) and for the treatment of Binge Eating Disorder (BED). Shire also will present health economic data on INTUNIV and outcomes research in ADHD. Vyvanse and INTUNIV should only be used to treat ADHD.

"Shire is committed to research in the field of neuroscience and developing treatment options for conditions that have significant unmet patient need, such as MDD and BED," said Arnaud Partiot, MD, PhD, Shire senior vice president, Research and Development.

Vyvanse is a once-daily prescription medication for patients ages 6 and above with Attention-Deficit/Hyperactivity disorder (ADHD) and may be used as part of a total treatment program that may include counseling or other therapies.

Vyvanse is a Schedule II controlled substance. CNS stimulants (amphetamines and methylphenidate-cont aining products) have a high potential for abuse and dependence. Assess the risk of abuse prior  to  prescribing and moni to r for signs of abuse and dependence.

INTUNIV is indicated for the treatment of ADHD as monotherapy and as adjunctive therapy to stimulant medications in children and adolescents ages 6 to 17. The effectiveness of INTUNIV for more than 8 weeks has not been systematically evaluated. The physician electing to use INTUNIV for extended periods should periodically reevaluate its long-term usefulness for the individual patient.

1 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.04 -1.20%
FB $117.56 -0.42%
GOOG $704.71 1.30%
TSLA $210.29 -5.50%
YHOO $37.02 2.80%


Chart of I:DJI
DOW 17,638.52 -22.19 -0.13%
S&P 500 2,042.95 -7.68 -0.37%
NASDAQ 4,695.9680 -21.1260 -0.45%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs